Abstract
Our previous study reported that an antitussive drug, dimemorfan, attenuates cholinergic dysfunction-induced amnesia in mice and acts like a sigma1 receptor agonist. This study further showed that dimemorfan (30 microM), like the putative sigma1 receptor agonist (+)-SKF-10047 (10 microM), significantly enhanced 25 mM KCl-evoked [3H]acetylcholine release from rat hippocampal but not striatal slices, which was antagonized by a sigma1 receptor antagonist haloperidol (0.3 microM).
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / pharmacology
-
Acetylcholine / metabolism*
-
Animals
-
Antipsychotic Agents / pharmacology
-
Atropine / pharmacology
-
Carbachol / pharmacology
-
Cholinergic Agonists / pharmacology
-
Dopamine Agonists / pharmacology
-
Dopamine Antagonists / pharmacology
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Haloperidol / pharmacology
-
Hippocampus / drug effects*
-
Hippocampus / metabolism
-
In Vitro Techniques
-
Male
-
Morphinans / pharmacology*
-
Muscarinic Antagonists / pharmacology
-
Phenazocine / analogs & derivatives*
-
Phenazocine / pharmacology
-
Potassium Chloride / pharmacology
-
Rats
-
Tritium / metabolism
Substances
-
Antipsychotic Agents
-
Cholinergic Agonists
-
Dopamine Agonists
-
Dopamine Antagonists
-
Morphinans
-
Muscarinic Antagonists
-
Tritium
-
dimemorfan
-
Potassium Chloride
-
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
-
SK&F 10047
-
Atropine
-
Carbachol
-
Phenazocine
-
Haloperidol
-
Acetylcholine